Molecular Profile Detail

Profile Name PDGFRA amp
Gene Variant Detail

PDGFRA amp (no effect)

Relevant Treatment Approaches PDGFR Inhibitor (Pan) PDGFR-alpha Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRA amp malignant peripheral nerve sheath tumor sensitive PDGFR Inhibitor (Pan) Imatinib Preclinical Actionable In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008). 16357008
PDGFRA amp lung small cell carcinoma sensitive PDGFR-alpha Inhibitor Ponatinib Preclinical Actionable In a preclinical study, Iclusig (ponatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973). 22328973
PDGFRA amp lung squamous cell carcinoma sensitive PDGFR Inhibitor (Pan) Dasatinib Preclinical - Cell line xenograft Actionable In a preclinical study, Sprycel (dasatinib) inhibited growth of a lung squamous cell cancer (SCC) cell line with amplification of PDGFRA in culture, and inhibited tumor growth in PDGFRA-amplified lung SCC xenograft models (PMID: 22328973). 22328973
PDGFRA amp lung squamous cell carcinoma sensitive PDGFR Inhibitor (Pan) Imatinib Preclinical Actionable In a preclinical study, Gleevec (imatinib) inhibited growth of lung squamous cell cancer cells with PDGFRA amplification in culture (PMID: 22328973). 22328973
PDGFRA amp non-small cell lung carcinoma sensitive PDGFR Inhibitor (Pan) Sunitinib Preclinical Actionable In a preclinical study, Sutent (sunitinib) decreased cell proliferation and inhibited downstream signaling in a NSCLC cell line harboring a PDGFRA amplification (PMID: 19366796). 19366796
Clinical Trial Phase Therapies Title Recruitment Status
NCT03352427 Phase II Dasatinib + Everolimus Everolimus Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations Recruiting
NCT01140568 Phase II Nilotinib Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas Terminated
NCT02626364 Phase II Crenolanib Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification Recruiting
NCT01306045 Phase II Erlotinib Lapatinib MK2206 Sunitinib Selumetinib Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies Recruiting
NCT02299141 Phase I Nintedanib Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer Recruiting